Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation ChemoFx assay (Precision Therapeutics Inc.) for prediction of response to chemotherapy for ovarian cancer. Lansdale: HAYES, Inc.. Healthcare Technology Brief Publication. 2014 Authors' conclusions Epithelial ovarian cancer is the leading cause of death from gynecologic malignancies. An estimated 21,980 new cases of ovarian cancer and 14,270 deaths from the disease are expected in the United States in 2014. In most cases, disease is widespread at the time of diagnosis. Estimated 5-year survival among patients with ovarian cancer is 44.6%; however, survival rates are much lower following early relapse. First-line treatment for ovarian cancer includes optimal debulking followed by multidrug chemotherapy with a platinum compound such as cisplatin or carboplatin and a taxane such as paclitaxel or docetaxel. The selection of chemotherapeutic agents is based on accumulated experience from clinical trials and treatment guidelines, but does not consider the sensitivity of the individual tumor to the agents selected. This generalized approach does not always lead to a partial or complete response, and patients with histologically similar tumors do not
necessarily respond similarly to treatments. For the majority of women with relapsed or recurrent disease, the choice of additional therapy depends on whether the tumor was sensitive or resistant to platinum compounds. To exploit the individual sensitivities of tumors, in vitro chemosensitivity testing has been developed to guide the selection of chemotherapeutic agents. In theory, selecting the most potent agents on the basis of chemosensitivity testing will lead to greater efficacy and overall survival (OS), and decrease toxicity from agents with limited efficacy. In practice, other factors affect responses to chemotherapy and ability to deliver treatment, such as concomitant medications, comorbidities, and blood supply to the tumor. Indexing Status Subject indexing assigned by CRD MeSH Antineoplastic Combined Chemotherapy Protocols; Drug Screening Assays, Antitumor; Drug-Related Side Effects and Adverse Reactions; Females; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Survival Rate Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence HAYES, Inc., 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218 Email: hayesinfo@hayesinc.com AccessionNumber 32015000341 Date abstract record published 11/03/2015 |